Lexicon Pharmaceuticals is a biopharmaceutical company. Co. discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. Co. is also developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. In addition, Co. is conducting preclinical research and development and preparing to conduct clinical development of compounds from a several additional drug programs. The LXRX stock yearly return is shown above.
The yearly return on the LXRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LXRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|